Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe PR Newswire - Thu Jul 16, 3:30PM CDT

WASHINGTON , July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA)...

VNDA : 5.45 (-6.84%)
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment PR Newswire - Wed Jul 15, 3:30PM CDT

WASHINGTON , July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention...

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit PR Newswire - Fri Jul 10, 3:30PM CDT

WASHINGTON , July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind,...

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S PR Newswire - Tue Jul 7, 3:30PM CDT

WASHINGTON , July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation...

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis PR Newswire - Wed May 27, 6:00AM CDT

WASHINGTON , May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation...

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences PR Newswire - Thu May 7, 5:44PM CDT

WASHINGTON , May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in May...

VNDA : 5.45 (-6.84%)
Vanda: Q1 Earnings Snapshot AP - Wed May 6, 3:07PM CDT

Vanda: Q1 Earnings Snapshot

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results PR Newswire - Wed May 6, 3:01PM CDT

WASHINGTON , May 6, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2026.

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals: Can Prescription Momentum Justify the Valuation Before Bysanti's Regulatory Verdict? Barchart - Tue May 5, 4:39PM CDT

Barchart Research What to Expect from VNDA Earnings VNDA Generated May 5, 2026 Current Price $7.39 EPS Estimate $$-0.53 Consensus Rating Moderate Buy Average Move 7.71% Vanda Pharmaceuticals: Can Prescription...

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years PR Newswire - Mon May 4, 7:00AM CDT

WASHINGTON , May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for...

VNDA : 5.45 (-6.84%)

Barchart Exclusives

This Dividend King With a 64-Year Streak Is Beating the Market Barchart - Thu Jul 16, 6:30PM CDT
This Dividend King continues to beat the market by pairing reliable income with consistent business growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.